Sunesis Pharmaceuticals is a biopharmaceutical company focused on the development of targeted inhibitors for the treatment of hematologic and solid cancers. Co.'s primary activities are conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology and conducting clinical trials. Co.'s primary program is vecabrutinib, a selective non-covalent inhibitor of Bruton's Tyrosine Kinase. Co. is also developing SNS-510, a phosphoinositide-dependent kinase-1 inhibitor licensed from Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited. We show 19 historical shares outstanding datapoints in our SNSS shares outstanding history coverage, used to compute SNSS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SNSS market cap history over the course of time is important for investors
interested in comparing SNSS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SNSS versus a peer is one thing; comparing
SNSS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SNSS can fluctuate over the course of history.
With this page we aim to empower investors researching SNSS by allowing them to research the SNSS market cap history. |
Free SNSS Email Alerts:
Video: The Importance of Market Cap
